Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the Erik Thun Group in connection with a shipping transaction with A.P. Möller Maersk
Mandate

Vinge advises the Erik Thun Group in connection with a shipping transaction with A.P. Möller Maersk

October 25, 2012

Vinge is advising the Erik Thun Group in connection with the acquisition of 13 oil and chemicals tankers from the A.P. Möller Maersk Group. The tankers are included in the Small Tanker Northwest Europe (8000 dwt) operational category and twelve are included in Dutch shipping companies jointly owned by Maersk and Thun. In connection with the acquisition, the Erik Thun Group will also acquire the salient parts of Broström AB’s business in Gothenburg which handle tanker maintenance and the employees in question will be offered employment.

Closing in respect of the transaction is conditional upon the consent of the Norwegian Competition Authority.

Vinge’s team consists of responsible partner Anders Strid, associates Anna Palmérus (competition) and Patrik Gargolinski (M&A).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025